Confirmed Attendees Include Hanmi Pharm, China Resources Double-Crane, Zhejiang University & More: Sneak Peek at AI FOR PHARMA Agenda Highlights | 2026BPD Chengdu

CurrentAI-driven drug discoveryWe've moved beyond single-point tool validation. The industry now focuses on how technology integrates with real-world business scenarios to address practical challenges in drug development, process scale-up, and compliant manufacturing.

Against this backdrop,2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrand Opening!AI for Pharma: Conference Agenda and Key Highlights Announced!Focus on how AI bridges the entire CMC pipeline—from drug discovery and process development to quality control and commercial manufacturing—to accelerate innovative drug R&D.

Gather on-site2000+Professional Buyers,70+Featuring distinguished speakers, the event offers a diverse lineup including technical forums, end-to-end exhibitions, and BPD Match sessions. Centered on technical presentations and case studies, it fosters CMC professional exchange, empowers emerging CMC talent, and builds an efficient platform focused on deep expertise to address real-world industry challenges.

Forum Schedule & Highlights

Highlights Preview

• End-to-End AI for Pharma
  From sequence optimization and delivery design in early drug discovery, through CMC process development and quality control, to commercial manufacturing and smart factory construction—the agenda covers the full AI-enabled biologics value chain, systematically sharing AI's value and integration logic across each stage.

• Emphasize compliance and implementation boundaries
  Featured session on AI digital compliance, CMC considerations, and implementation boundaries—addressing the industry's shift from "AI that works" to "AI that complies." Amid tightening regulations, we help enterprises define feasible application boundaries and establish clear compliance pathways.

• Highlight real-world enterprise experience sharing

  Companies such as Combi, Qide Pharma, Hengli Bio, China Resources Shuanghe, and Pedebio have gathered in 2026BPD Chengdu to share real-world AI drug discovery cases, providing attendees with actionable and valuable practical experience.

AI for Pharma Forum Schedule

Schedule updated through 9/29

AI In Drug Discovery

Report: Pending

Guest: Liu Qihé, TransBio, Head of AI Development

Report: Natural Peptide Library & AI Discovery Platform

Guest: Liu Lulu, BD Director, PedBio

AI In Drug Discovery

Report: Generative AI-Driven Antibody De Novo Design

Guest: Wang Tianyuan, CEO of Combiotech

Report: AI-Driven Drug Discovery and Clinical Translation

Guest: Liang Zhang, Researcher at the Hangzhou Institute of Medicine, Chinese Academy of Sciences

Report: The AI-Driven "Dry-Wet Closed Loop" Paradigm

Guest: Zhang Shuihua, Vice President of NewYue Bio

Report: Intelligent Automation Discovery Platform – Differentiated Discovery Strategies for Next-Generation ADC/XDC Drugs

Guest: Zhang Hongwei, Chief Information Officer and Managing Director of Beijing at Kede Pharma

AI-Enabled CMC Development for Biopharmaceuticals

Report: Study on AI Digitalization, Compliance, and Business Impact

Guest: Ma Jun, former Vice President of Junshi Biosciences

Report: AI-Enabled Biopharmaceutical CMC and Regulatory Considerations

Guest: Dongqiang Lin, Zhejiang University, Professor

Interview: Building Smart Factories

Guest: Zhang Hong, Senior Director of Digital Development Center for Human Drug Formulations, Qilu Pharmaceutical

AI-Driven Commercial Biopharmaceutical Manufacturing

Report: Digital Transformation of Biopharmaceutical Manufacturing: Practices and Insights from Henlius.

Guest: Wei Gong, General Manager of ADC Development and Clinical Manufacturing at MacroGenics

Report: The Path and Practice of Digital Intelligence Advancement for Pharmaceutical Enterprises

Guest: Zhu Xiaofeng, Deputy General Manager of the Intelligent Data Department, China Resources Double Crane